
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Your AI-Trained Oncology Knowledge Connection!


Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss progression patterns and therapies after lorlatinib in ALK-positive NSCLC.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for NVL-655 in ALK-positive NSCLC and other ALK-positive solid tumors.

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss testing for ALK-positive and ROS1-positive non–small cell lung cancer.

Benjamin Besse, MD, PhD, discusses mechanisms of resistance to amivantamab plus lazertinib vs osimertinib in patients with EGFR-mutant, advanced NSCLC.

The ARROS-1 Phase 1/2 study investigates the safety, tolerability, and efficacy of zidesamtinib (NVL-520), a ROS1-selective, brain-penetrant tyrosine kinase inhibitor, in heavily pre-treated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors, showing promising durable responses in both systemic and intracranial disease.

Benjamin Besse, MD, PhD, discusses findings from the phase 3 CARMEN-LC03 trial.

Benjamin Besse, MD, discusses the results of an ad-hoc safety analysis of the phase 1/2 LIBRETTO-001 trial, which examined the use of selpercatinib in patients with RET-altered advanced medullary thyroid cancer and non–small cell lung cancer.

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of necitumumab (Portrazza) and abemaciclib (Verzenio) in patients with stage IV non–small cell lung cancer.

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses challenges facing the treatment of patients with stage IV non

Benjamin Besse, MD, Institut Gustave Roussy, Villejuif, Paris Sud University, discusses the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with non

Published: September 11th 2024 | Updated:

Published: September 30th 2024 | Updated:

Published: September 20th 2017 | Updated:

Published: May 17th 2018 | Updated:

Published: April 13th 2018 | Updated: